Telomir Pharmaceuticals, Inc. (TELO) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Telomir Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing small-molecule therapeutics for cancer and age-related diseases. Its lead candidate, Telomir-1 (Telomir-Zn), targets triple-negative breast cancer (TNBC). The company received FDA clearance for an Investigational New Drug (IND) application to initiate clinical trials. This report covers the quarterly period ended March 31, 2026. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(990,947) | $(2,179,828) |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.07) |
| Operating Expenses | $1,041,336 | $2,187,782 |
| Research & Development (R&D) | $467,797 | $336,996 |
| General & Administrative (G&A) | $573,539 | $1,850,786 |
| Cash and Cash Equivalents (End of Period) | $5,560,511 | $402,999 |
| Net Cash Used in Operating Activities | $(1,773,510) | $(863,132) |
| Total Current Liabilities | $827,310 | $1,427,991 |
| Stockholders' Equity | $4,962,226 | $(161,105) |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $1.19 million (55%) compared to Q1 2025, primarily driven by a significant reduction in G&A expenses.
- G&A Expense Reduction: G&A expenses dropped from $1.85 million to $0.57 million. The prior year included approximately $1.38 million in stock-based compensation for new options granted, whereas Q1 2026 stock-based compensation was only $39,803.
- Increased R&D Spend: R&D expenses increased by $130,801 (39%) to $467,797, reflecting continued investment in pre-clinical research and toxicology studies.
- Liquidity Improvement: Cash balances increased significantly from $402,999 in Q1 2025 to $5.56 million in Q1 2026, bolstered by equity financings in 2025 and interest income of $51,644 in the current quarter.
- Liability Reduction: Total current liabilities decreased by $600,681, largely due to the repayment of $417,470 in accrued officer compensation and $155,518 in amounts due to an officer.
Outlook, Risks, and Subsequent Events
Subsequent Events (Post-March 31, 2026):
- TELI Merger: On April 22, 2026, the company consummated a merger with TELI Pharmaceuticals, Inc., acquiring global rights to Telomir-1. The company issued 34,389,710 restricted shares to former TELI stockholders.
- Funding Commitment: Bayshore Trust contributed $1.0 million at closing and entered a binding commitment to invest up to an additional $4.0 million contingent on regulatory (IND acceptance) and clinical (Phase 1/2 initiation) milestones.
- ATM Offering: Between April 1 and May 13, 2026, the company sold 4,275 shares via its ATM facility for net proceeds of approximately $6,000.
Liquidity and Going Concern:
Management states that as of the filing date, the company has insufficient cash to support operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. The company expects to fund operations through the first quarter of 2027 based on current cash and the recent TELI merger funding, but additional financing is required for long-term sustainability.
Risks:
- Dependence on external funding to continue operations and clinical trials.
- Uncertainty regarding the success of clinical trials and regulatory approval for Telomir-1.
- Reliance on related parties for financing and intellectual property licensing.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional capital beyond the $1.0 million immediate contribution from the TELI merger and the contingent $4.0 million milestone funding.
- TELI Merger Accounting: Monitor the final accounting treatment of the TELI acquisition (asset acquisition vs. business combination) and the impact on share count and dilution.
- Related Party Transactions: Review the terms of the license agreement with MIRALOGX (8% royalty) and the funding commitments from Bayshore Trust and Starwood Trust.
- Cash Burn Rate: Assess the sustainability of the current cash burn rate (~$1.8 million per quarter) against the $5.6 million cash balance.
- Stock-Based Compensation: Note the volatility in G&A expenses due to stock-based compensation, which was a major driver of the loss in Q1 2025 but minimal in Q1 2026.